NasdaqGS:KLDO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Kaleido Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KLDO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

53.5%

KLDO

-2.3%

US Pharmaceuticals

-0.8%

US Market


1 Year Return

18.5%

KLDO

11.3%

US Pharmaceuticals

13.8%

US Market

Return vs Industry: KLDO exceeded the US Pharmaceuticals industry which returned 11.3% over the past year.

Return vs Market: KLDO exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

KLDOIndustryMarket
7 Day53.5%-2.3%-0.8%
30 Day36.2%-3.5%-5.7%
90 Day20.1%4.3%8.6%
1 Year18.5%18.5%14.2%11.3%16.4%13.8%
3 Yearn/a24.9%15.6%36.9%27.8%
5 Yearn/a43.0%26.4%85.0%64.2%

Price Volatility Vs. Market

How volatile is Kaleido Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kaleido Biosciences undervalued compared to its fair value and its price relative to the market?

6.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KLDO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KLDO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KLDO is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: KLDO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KLDO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KLDO is overvalued based on its PB Ratio (6.1x) compared to the US Pharmaceuticals industry average (2.9x).


Next Steps

Future Growth

How is Kaleido Biosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

24.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KLDO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KLDO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KLDO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KLDO's revenue (48.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: KLDO's revenue (48.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KLDO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Kaleido Biosciences performed over the past 5 years?

-42.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KLDO is currently unprofitable.

Growing Profit Margin: KLDO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KLDO is unprofitable, and losses have increased over the past 5 years at a rate of 42.1% per year.

Accelerating Growth: Unable to compare KLDO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KLDO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: KLDO has a negative Return on Equity (-155.77%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kaleido Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: KLDO's short term assets ($77.2M) exceed its short term liabilities ($11.5M).

Long Term Liabilities: KLDO's short term assets ($77.2M) exceed its long term liabilities ($24.2M).


Debt to Equity History and Analysis

Debt Level: KLDO's debt to equity ratio (40.2%) is considered high.

Reducing Debt: Insufficient data to determine if KLDO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KLDO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KLDO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 42.6% each year.


Next Steps

Dividend

What is Kaleido Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KLDO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KLDO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KLDO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KLDO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KLDO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Kaleido Biosciences has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Bonney
Executive Chair & Office of Ceo2.08yrsUS$397.50k4.44%
$ 14.1m
Geoffrey von Maltzahn
Co-Founder & Director5.08yrsUS$35.00k0.96%
$ 3.1m
Jerald Korn
General Counsel & Corporate Secretary1.17yrsUS$1.68mno data
Alison Lawton
Special Advisor For Office of CEO & Director2.08yrsUS$2.89m0.46%
$ 1.5m
Katharine Knobil
Chief Medical Officer and Head of Research & Development1.75yrsUS$1.25m0%
$ 0
William Duke
Chief Financial Officer0.83yrno datano data
Johan Hylckama Vlieg
Chief Scientific Officer1.17yrsno datano data
Susan Stewart
Chief Regulatory Affairs Officer2.42yrsno datano data
Clare Fisher
Chief Business Officer1.42yrsno datano data

1.2yrs

Average Tenure

56yo

Average Age

Experienced Management: KLDO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Bonney
Executive Chair & Office of Ceo2.08yrsUS$397.50k4.44%
$ 14.1m
Geoffrey von Maltzahn
Co-Founder & Director5.08yrsUS$35.00k0.96%
$ 3.1m
Alison Lawton
Special Advisor For Office of CEO & Director2.08yrsUS$2.89m0.46%
$ 1.5m
Theodose Melas-Kyriazi
Independent Director1.17yrsUS$468.03k0.094%
$ 297.3k
Laurie Glimcher
Member of Scientific Advisory Board1.67yrsno datano data
C. Kahn
Member of Scientific Advisory Board1.67yrsno datano data
Bonnie Bassler
Independent Director1.75yrsUS$39.00k0%
$ 0
Grady Burnett
Independent Director2yrsUS$46.25k0%
$ 0
Anthony Quinn
Independent Director4.58yrsUS$48.75k0.089%
$ 281.9k
Laura Kiessling
Member of Scientific Advisory Board1.67yrsno datano data
Fergus Shanahan
Chairman of Scientific Advisory Board1yrno datano data
Robert Jenq
Member of Scientific Advisory Board1.67yrsno datano data

1.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: KLDO's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.3%.


Top Shareholders

Company Information

Kaleido Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kaleido Biosciences, Inc.
  • Ticker: KLDO
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$317.076m
  • Shares outstanding: 35.55m
  • Website: https://www.kaleido.com

Number of Employees


Location

  • Kaleido Biosciences, Inc.
  • 65 Hayden Avenue
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KLDONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2019

Biography

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 05:21
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.